Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2006

View Archived Issues

MCB-3837 and MCB-3681 yield promising results against Gram-positive strains

Dong-A expects to commence phase I development of DA-7218 in 2006

Bristol-Myers Squibb completes rolling NDA for dasatinib

YM-477: new orally active TPO agonist

Johnson & Johnson and Guidant merger statement declared effective

Candidate drug selected in Medivir's HCV collaboration with Tibotec

Phase IIa study begins for topical PTH (1-34)

Update on Maxim and EpiCept merger

sanofi-aventis and Regeneron amend VEGF Trap agreement

NitroMed and Boston Scientific conclude research collaboration

Novel agents for treating neurodegenerative disorders disclosed in recent Migenix patent

Recent patents cover novel treatment options for cancer

Novel agents with potential for the treatment of anxiety, depression, etc.

Further studies of NPI-0052 presented

New histamine H3 receptor ligands emerge from Banyu R&D

Primary endpoint data from phase II/III trial for Dynavax's Heplisav

LY-517717: A novel prophylactic for VTE following major orthopedic surgery

FDA approval for Vaprisol in euvolemic hyponatremia

EDO-P4 demonstrates broad antifungal activity

Genentech submits BLA for Lucentis in wet AMD

Data from several lenalidomide studies presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...